Member Info for mbingo

It may not seem like it sometimes but stated strategy on company website is : Urals Energy's objective is to increase shareholder value by focusing on development of its foundation of proven and probable reserves (2P). Urals Energy is looking to make acquisitions and seek exploration licences to increase and broaden its portfolio and provide potential shareholder upside where the potential for significant recoverable reserves exists. " They have the reserves. The partnerships will come. Oil price recovering nicely. Success in that they already produce 2000 BOPD. Tight float, plenty of opportunity and seriously cheap!!!

Interim readouts won't necessarily be discussed on Wednesday but due this month.

Heavily backed by institutions and directors , two phase II read outs this year. Interim results from one of those due this month. IPO was at 37p. Directors buying at 22.5p. Billion USD markets. "Open trial" taking place re first read out. Opportunity to sell out much earlier. Cashed up for the results of the two phase II trials. Likely to be acquisition target if possitive readouts. Broker target of 113p by Northwest. Tight float....

Very happy with the 0.1075 buy-in price available. 2-3 times upside in my book and little downside.

Good to see strong support at this level. Massive upside here if all goes to plan re interim data readout due towards end June. Directors bought in at 22. IPO at 37. Heavily backed by institutions, tight float. Potential takeover target. Some risk sure but upside huge!

Accumulation going on here

No stock around. Looks like this is heading up. Will we break through the resistance at 25...

Looks set for a run now - and why not. Risk v Reward clearly in investors favour. So undervalued, even at 200 in my view.

This has spent some time consolidating at around this level. Original IPO priced these at 37p a share. Directors were buying at 22.5p in 2016. Phase 2 results a few weeks away perhaps. Heavily supported by institutional investors, with a low free float and having consolidated nicely, the Company looks well placed to go on a run in the lead to results.

Good news! This has to be an acquisition target in this oil price environment.

Just needs a spark. Incredibly undervalued imo. Some company PR wouldn't go amiss..

So, to keep some balance, What are the downside risks? Russia as a political risk factor.. ok. Russian Tax - excise tax at Arctineft has to be paid before any shipment and the price of oil is determined for 5 days once tanker has left. A major drop in oil price between a) and b) has a negative impact. This is not an ideal risk. Still net back from last tanker to Urals was USD 8m. U.K. Russia relations ... But at 12m market cap, 2000 BOPD, owner of two refineries, assets at £60m plus, a Q2 drill, 200m reserves + endorsed via CPR, oil price close to 80$, low free float, 5% ebitda dividend, desire to partner to realise value from reserves R v R well in favour of investor in my book.

Yeah, it did sound like it was going to be a busy few weeks in that interview.

Bangers, based on stable current prices for Brent, Urals will generate in the region of USD 20m cash from their Articneft operation alone through July and October after taxes. Petrossakh still generates cash at circa US$2 above Dubai benchmark for 950 BOPD. Taxes to be paid. Then drill and partner opps! In my view cask should be equivalent to USD 15m market cap with no debt by October. ### Value !!

Can anyone outline the investment case here for wressle? What does planning potentially give them? The biscanthorpe drill I understand. Thanks

Agreed. Above the sale price, also at 14.03

They had EUR 18m cash at March 2018. Market cap here is about double that for all their IP etc. Bottom is in in my view..

The independent CPR can be the basis for discussion with potential partners. Plenty for JV partners to review. This should be 250-350 minimum (assuming some risk in jurisdiction) in my view. Sub 100 is a joke.

Vast director buys in 2017 at prices well in excess of this clearly demonstrate their view on company valuation. Double bottom in, Risk vs reward at this price makes it a clear BUY for me.

For anyone interested in reviewing the comments on May 11th: " Early analysis of certain biomarker indicators suggest that the treatment did not produce the expected interferon-beta bioactivity in the treatment group that was previously seen in Faron's Phase I/II trial for Traumakine. It is still too early to understand why this is the case and there are a number of possible causes that the Company are investigating including, inter alia, formulation, administration and deactivation. Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis. Faron will provide an update with further information in due course." To me, given these comments, there may well be a reasonable explanation. We will see. Either way, market cap at 37m currently, 13.5% of the market cap pre May 8th RNS. That's a massive discount. Given cash, assets, other prospects, surely this is a massive overreaction.